Numerous studies examining anthracycline-induced CHF included cancer patients who received monoclonal antibodies targeting the HER2 domain, potentially leading to an overestimation of anthracycline’s cardiotoxicity risk [25,26]. This evidence concerns the gene ERBB2 and cancer.